Pegasparaginase: where do we stand?

Author： Zeidan Amer   Wang Eunice S   Wetzler Meir  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.9, Iss.1, 2009-01, pp. : 111-119

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunotherapy and immunoprevention of cancer: where do we stand?

By Cavallo Federica   Curcio Claudia   Forni Guido  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 5, 2005-05 ,pp. : 717-726

Informa Healthcare

Access to resources Recommend Favorite

Uterus transplantation: where do we stand today and where should we go?

By Brännström Mats   Wranning Caiza Almén  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 4, 2007-04 ,pp. : 427-429

Informa Healthcare

Access to resources Recommend Favorite

Perspectives on MAO-B in aging and neurological disease: Where do we go from here?

By Kumar M.   Andersen Julie  

Molecular Neurobiology, Vol. 30, Iss. 1, 2004-08 ,pp. : 77-89

Humana Press, Inc

Access to resources Recommend Favorite

Structure and function of xanthine oxidoreductase: where are we now?

By Harrison R.  

Free Radical Biology and Medicine, Vol. 33, Iss. 6, 2002-09 ,pp. : 774-797

Elsevier

Access to resources Recommend Favorite

Peg-asparaginase for acute lymphoblastic leukemia

By Rytting Michael  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 5, 2010-05 ,pp. : 833-839

Informa Healthcare

Access to resources Recommend Favorite